GetTopicDetailResponse(id=002580e74dd, topicName=聚乙二醇化干擾素, introduction=聚乙二醇化干擾素, content=null, image=null, comments=3, allHits=991, url=https://h5.medsci.cn/topic?id=80774, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=78859, tagList=[TagDto(tagId=78859, tagName=聚乙二醇化干擾素)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2055409, encodeId=32d72055409bc, content=<a href='/topic/show?id=002580e74dd' target=_blank style='color:#2F92EE;'>#聚乙二醇化干擾素#</a>, objectTitle=Clinica Chimica Acta：白蛋白-膽紅素評(píng)分與慢性乙型肝炎患者對(duì)聚乙二醇化干擾素和核苷類似物的反應(yīng)有關(guān), objectType=article, longId=192144, objectId=eefa19214401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eefa19214401, replyNumber=0, likeNumber=83, createdTime=2021-02-24, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eefa19214401, moduleTitle=Clinica Chimica Acta：白蛋白-膽紅素評(píng)分與慢性乙型肝炎患者對(duì)聚乙二醇化干擾素和核苷類似物的反應(yīng)有關(guān), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=eefa19214401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055408, encodeId=7d5420554081d, content=<a href='/topic/show?id=002580e74dd' target=_blank style='color:#2F92EE;'>#聚乙二醇化干擾素#</a>, objectTitle=JCO：Pembrolizumab和聚乙二醇化干擾素α-2b在晚期黑色素瘤中的Ib / II期研究, objectType=article, longId=151983, objectId=6e2e151983a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e2e151983a4, replyNumber=0, likeNumber=76, createdTime=2019-07-09, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e2e151983a4, moduleTitle=JCO：Pembrolizumab和聚乙二醇化干擾素α-2b在晚期黑色素瘤中的Ib / II期研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6e2e151983a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055407, encodeId=321f205540e4c, content=<a href='/topic/show?id=002580e74dd' target=_blank style='color:#2F92EE;'>#聚乙二醇化干擾素#</a>, objectTitle=Eiger制藥宣布首例患者入組聚乙二醇化干擾素聯(lián)合Ritonavir-Boosted Lonafarnib的II期LIFT研究, objectType=article, longId=146130, objectId=8c0f14613063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0f14613063, replyNumber=0, likeNumber=75, createdTime=2019-05-04, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0f14613063, moduleTitle=Eiger制藥宣布首例患者入組聚乙二醇化干擾素聯(lián)合Ritonavir-Boosted Lonafarnib的II期LIFT研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8c0f14613063)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
